--- canonical_name: Avanafil alternate_names: Stendra, Spedra, Zepeed, TA-1790 canonical_topic: Avanafil for Health & Longevity short_topic_lc: avanafil creation_date: 2026-0925-1733 creator_ai_fullname: Opus 5.5 ep_keywords: PDE5 Inhibitors, Phosphodiesterase Type 5 Inhibitors, Erectile Dysfunction Medications --- # Avanafil for Health & Longevity
Evidence Review created on 09/25/2026 using [AI4L](https://github.com/forever-healthy/AI4L) / Opus 5.5 **Also known as:** Stendra, Spedra, Zepeed, TA-1790 ## Motivation Avanafil (sold as Stendra and Spedra) is a prescription medication for erectile dysfunction. It belongs to the same drug family as sildenafil and tadalafil and works by blocking an enzyme that ends an erection, which helps blood flow into the penis during arousal. It draws interest because it acts within minutes and wears off within hours, a profile suited to spontaneous sexual activity with fewer lingering effects the next day. Approved in the United States in 2012, avanafil is the newest and least studied of the widely used drugs in its family. Erectile function is closely tied to blood vessel health, and the wider drug family has drawn attention for possible benefits to the heart and brain, raising the question of whether avanafil shares them. This review examines what is known about avanafil's benefits, risks, interactions and practical use for health-focused adults who want to stay sexually active as they age, and how far the evidence supports a role for it beyond sexual function. **[Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol) - [Conclusion](#conclusion)** ## Recommended Reading Expert podcast episodes, narrative reviews and primary research that discuss avanafil's pharmacology, clinical use and place among erectile dysfunction drugs in depth. * [Dr. Michael Eisenberg: Improving Male Sexual Health, Function & Fertility](https://www.hubermanlab.com/episode/dr-michael-eisenberg-improving-male-sexual-health-function-fertility) - Andrew Huberman A Stanford urologist names avanafil among first-line phosphodiesterase type 5 (PDE5) inhibitors (drugs that block the enzyme ending an erection) and compares the class on on-demand versus daily use, onset, clearance and side effects. * [#260 β€’ Men’s Sexual Health: why it matters, what can go wrong, and how to fix it – Mohit Khera, M.D., M.B.A., M.P.H.](https://peterattiamd.com/mohitkhera/) - Peter Attia Urologist Mohit Khera traces the history and mechanisms of erectile dysfunction drugs, the PDE5 inhibitor class that includes avanafil, and links erectile dysfunction to cardiovascular disease and testosterone. * [Avanafil for erectile dysfunction in elderly and younger adults: differential pharmacology and clinical utility.](https://pubmed.ncbi.nlm.nih.gov/25210457/) - Katz et al., 2014 Reviews avanafil's pharmacology and trial results with attention to older men, arguing that its fast onset and short action suit men with several chronic conditions. * [A comparison of the available phosphodiesterase-5 inhibitors in the treatment of erectile dysfunction: a focus on avanafil.](https://pubmed.ncbi.nlm.nih.gov/26316720/) - Evans & Hill, 2015 Compares avanafil with the other PDE5 inhibitors on onset, food effects, selectivity, side effects and patient preference. * [Selectivity of avanafil, a PDE5 inhibitor for the treatment of erectile dysfunction: implications for clinical safety and improved tolerability.](https://pubmed.ncbi.nlm.nih.gov/22759639/) - Wang et al., 2012 Links laboratory selectivity data against other phosphodiesterase enzymes to trial side-effect rates; co-authored by employees of VIVUS and Mitsubishi Tanabe, the drug's licensee and developer. No avanafil content was found from Rhonda Patrick, Chris Kresser, Life Extension Magazine or Lifespan.io; their site searches returned no results, and Life Extension's erectile dysfunction protocol covers the drug class only briefly without naming avanafil. ## Grokipedia * [Avanafil](https://grokipedia.com/page/Avanafil) AI-generated encyclopedia entry summarizing avanafil's approval history, rapid onset, dosing, contraindications and common side effects; useful for quick orientation, though its claims need checking against primary sources. ## Examine No Examine article on avanafil exists. Examine.com does not typically cover prescription medications. ## ConsumerLab No ConsumerLab article on avanafil exists. ConsumerLab does not typically cover prescription medications. ## Systematic Reviews The systematic reviews and meta-analyses (studies pooling results from many trials; network versions compare several drugs at once) below cover avanafil's efficacy and side effects, its ranking against other erectile dysfunction drugs, and two class-wide questions: heart outcomes and melanoma (the most dangerous skin cancer). * [Avanafil for the Treatment of men With Erectile Dysfunction: A Systematic Review and Meta-analysis of Randomized Controlled Trials.](https://pubmed.ncbi.nlm.nih.gov/31672076/) - Li et al., 2019 Pools 8 trials in 3,709 men: avanafil improved erection and intercourse success over placebo, with more side effects and a modest edge for 200 mg. * [The Efficacy and Safety of Avanafil During a Treatment of Male Erectile Dysfunction: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.](https://pubmed.ncbi.nlm.nih.gov/37484697/) - Warli et al., 2023 The most recent avanafil-only pooling, 11 trial publications: avanafil beat placebo on erectile scores and intercourse success, with modestly more side effects. * [A comparative evaluation of on-demand phosphodiesterase-5 inhibitor efficacy in erectile dysfunction treatment: a systematic review and network meta-analysis of double-blind, placebo-controlled, randomized trials.](https://pubmed.ncbi.nlm.nih.gov/42296271/) - Salonia et al., 2026 Ranks sildenafil most effective and avanafil least across 83 trials; two authors are employees of Viatris, which sells Viagra (sildenafil). * [Long-term effects of phosphodiesterase-5 inhibitors on cardiovascular outcomes and death: a systematic review and meta-analysis.](https://pubmed.ncbi.nlm.nih.gov/38777751/) - Soulaidopoulos et al., 2024 Sixteen cohorts (groups followed over time), 1.26 million people: users of avanafil's drug class had fewer cardiovascular events and deaths; causation remains unproven. * [The relationship between the history of PDE5-inhibitors assumption and melanoma: a systematic review.](https://pubmed.ncbi.nlm.nih.gov/37982667/) - Cilio et al., 2023 Of eight human studies of avanafil's drug class, five linked use to higher melanoma risk and three found none; other explanations remain possible. ## Mechanism of Action Avanafil acts on the nitric oxide pathway (the chemical relay that relaxes blood-vessel muscle). Sexual stimulation releases nitric oxide (a signaling gas) from penile nerves and vessel linings; it activates guanylate cyclase (an enzyme), which produces cyclic guanosine monophosphate (cGMP, a messenger that relaxes smooth muscle). Relaxed muscle lets blood fill the erectile tissue. PDE5 breaks down cGMP and ends the erection; avanafil competitively blocks PDE5 so cGMP persists. Without sexual stimulation little cGMP forms, and avanafil produces no erection. * **Selectivity:** more than 100-fold preference for PDE5 over PDE6 (the retinal enzyme behind color-vision changes) and over 10,000-fold over PDE1 (a heart and vessel enzyme degrading cell messengers) and PDE11 (a similar enzyme in muscle and testis) ([Wang et al., 2012](https://pubmed.ncbi.nlm.nih.gov/22759639/)). * **Absorption:** peak blood levels at 30–45 minutes; a high-fat meal delays the peak by about 1 hour and lowers it by 39%. * **Half-life:** about 5 hours (time for blood levels to fall by half), far shorter than tadalafil's. * **Distribution and metabolism:** 99% bound to plasma proteins, with trace amounts in semen; cleared by the liver mainly through CYP3A4 (the main liver enzyme that breaks down many drugs), with minor help from CYP2C enzymes (a related liver-enzyme family). Supporters argue that this selectivity reduces off-target side effects, but comparative meta-analyses have not consistently confirmed a tolerability advantage ([Salonia et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42296271/)). Because PDE5 also sits in blood vessels and platelets, the class shares mild vasodilation (blood-vessel widening) and a small blood-pressure drop. ## Historical Context & Evolution Avanafil (development code TA-1790) was discovered by Tanabe Seiyaku, now Mitsubishi Tanabe Pharma, and licensed to the US company VIVUS in 2001. It was designed as a "second-generation" PDE5 inhibitor: faster than sildenafil, shorter-acting than tadalafil and more selective for its target enzyme. South Korea approved it in 2011 as Zepeed, the US Food and Drug Administration (FDA) in April 2012 as Stendra, and the European Medicines Agency in 2013 as Spedra. A later US label update allowed dosing about 15 minutes before sexual activity, based on a dedicated VIVUS-sponsored [onset trial](https://pubmed.ncbi.nlm.nih.gov/25591992/). Its original and only approved use is erectile dysfunction. Interest from health-focused adults has two sources. Erectile function is tied to blood-vessel health and to quality of life in later decades. The wider class, whose first member sildenafil was developed for angina (chest pain from reduced heart blood flow), has also drawn attention for possible vascular, metabolic and brain effects, based largely on observational studies (which track users without assigning treatment) of sildenafil and tadalafil. The early expectation that selectivity would mean clearly fewer side effects has since been tested. [Some meta-analyses](https://pubmed.ncbi.nlm.nih.gov/26646748/) support lower rates of certain adverse events, while a [2026 network meta-analysis](https://pubmed.ncbi.nlm.nih.gov/42296271/) (comparing several drugs through shared comparisons), co-authored by employees of a competitor, ranked avanafil below sildenafil and tadalafil. Head-to-head trials remain few, and [one](https://pubmed.ncbi.nlm.nih.gov/35080051/), sponsored by generic maker Zydus, found avanafil superior to sildenafil, so its relative standing is still open. ## Expected Benefits ### High 🟩 🟩 🟩 #### Improved Erectile Function Avanafil improves the ability to achieve and keep an erection firm enough for intercourse across mild-to-severe erectile dysfunction, including men with diabetes and after nerve-sparing prostate surgery. Randomized controlled trials (RCTs, studies assigning treatment by chance) and their [meta-analysis](https://pubmed.ncbi.nlm.nih.gov/31672076/) show consistent gains, with effects from about 15 minutes after dosing ([Hellstrom et al., 2015](https://pubmed.ncbi.nlm.nih.gov/25591992/)) sustained over 52 weeks ([Belkoff et al., 2013](https://pubmed.ncbi.nlm.nih.gov/23521325/)). Most pivotal trials were sponsored by VIVUS, the US license holder, a direct financial conflict of interest. Gains are smaller in diabetes and after prostatectomy (prostate removal). **Magnitude:** Across 8 RCTs (3,709 men), the IIEF-EF score (International Index of Erectile Function, erectile-function domain, a validated 30-point questionnaire) rose 4.57 points more than placebo (95% CI 3.68–5.46; CI, confidence interval, the range likely to contain the true effect), and successful intercourse was 2.53 times as likely (RR 2.53; RR, relative risk, the ratio of event rates between groups). ### Medium 🟩 🟩 No benefit reaches Medium: apart from erectile function, avanafil's human outcome data come from observational studies of the whole drug class or from biomarker-only trials, not from controlled avanafil trials with clinical endpoints. ### Low 🟩 #### Fewer Cardiovascular Events and Deaths Cohorts of men using avanafil's drug class show fewer heart attacks, heart-failure events and deaths ([Soulaidopoulos et al., 2024](https://pubmed.ncbi.nlm.nih.gov/38777751/)). The data are observational, dominated by sildenafil and tadalafil, and open to healthy-user bias (healthier men being likelier to receive the drug); no avanafil data exist. **Magnitude:** Pooled RR 0.78 (95% CI 0.69–0.89) for major adverse cardiovascular events across 16 cohort studies of 1.26 million people, and 0.70 (95% CI 0.56–0.87) for all-cause mortality across 13 of them. #### Lower Alzheimer's Disease Risk ⚠️ Conflicted Among 269,725 UK men with erectile dysfunction, starting a drug in avanafil's class was linked with lower Alzheimer's risk, lost with a three-year lag ([Adesuyan et al., 2024](https://pubmed.ncbi.nlm.nih.gov/38324745/)). A Medicare cohort found no association ([Desai et al., 2022](https://pubmed.ncbi.nlm.nih.gov/36330433/)). Net reading: protection is unproven; avanafil was never analyzed separately. **Magnitude:** HR 0.82 (95% CI 0.72–0.93; HR, hazard ratio, the relative rate of new cases over time) for initiators versus non-users; HR 0.93 (95% CI 0.80–1.08) with a three-year lag; HR 0.99 (95% CI 0.69–1.43) in the Medicare cohort. #### Modest Blood Pressure and Vascular-Function Improvement Randomized trials of the drug class show small reductions in blood pressure and arterial stiffness and better artery dilation ([Zhang et al., 2025](https://pubmed.ncbi.nlm.nih.gov/41469737/)). Nearly all involve sildenafil and tadalafil; one 4-week [trial](https://pubmed.ncbi.nlm.nih.gov/33112433/) of daily avanafil improved only unvalidated endothelial (blood-vessel lining) markers, so on-demand effects remain uncertain. **Magnitude:** Across 63 RCTs, systolic blood pressure (the upper number) fell 2.80 mmHg and flow-mediated dilation (artery widening in response to blood flow) rose 2.47 percentage points versus placebo. ### Speculative 🟨 ## Benefit-Modifying Factors * **Genetic polymorphisms:** In one sildenafil study, carriers of the ACE D allele (a variant of the gene for angiotensin-converting enzyme, a blood-pressure regulator) responded less often ([Eisenhardt et al., 2003](https://pubmed.ncbi.nlm.nih.gov/12837457/)); no avanafil data exist. * **Testosterone level:** Low testosterone is a common reason for poor response to drugs in this class; correcting documented deficiency can restore response. * **Glucose control:** Men with diabetes improved on avanafil but less than men without it; a high HbA1c (glycated hemoglobin, a three-month average of blood sugar) predicts a weaker response. * **Baseline severity:** Men with mild or moderate dysfunction reach normal function more often than those with severe dysfunction, although gains appear at every severity level. * **Sex:** Only men have been studied; no evidence supports benefit in women, and the drug is not indicated for them. * **Pre-existing conditions:** After nerve-sparing prostatectomy (prostate removal preserving erection nerves), spinal cord injury or advanced atherosclerosis (artery plaque buildup), response is lower because erection requires intact nerves and responsive vessels. * **Age:** Trials enrolled men up to their late 80s, and about 23% were 65 or older with similar efficacy; age-related vascular disease and lower testosterone still narrow the achievable benefit. ## Potential Risks & Side Effects ### High πŸŸ₯ πŸŸ₯ πŸŸ₯ #### Headache, Flushing, and Nasal Congestion PDE5 inhibition widens vessels in the head, face and nasal lining, producing headache, flushing, nasal congestion and nasopharyngitis (inflammation of the nose and throat); back pain occurs less often. Multiple RCTs, including a VIVUS-sponsored phase 3 trial ([Goldstein et al., 2012](https://pubmed.ncbi.nlm.nih.gov/22248153/)), and a [meta-analysis](https://pubmed.ncbi.nlm.nih.gov/31672076/) document these effects. They are usually mild, transient and more common at 200 mg; about 2–3% of men stopped for side effects. **Magnitude:** Treatment-emergent adverse events (side effects arising during treatment) were 1.78 times as frequent as with placebo (RR 1.78, 95% CI 1.38–2.31); headache affected 5.1–10.5% of men depending on dose versus 1.7% on placebo. #### Low Blood Pressure, Especially With Nitrates Avanafil lowers blood pressure slightly and sharply amplifies the drop from nitrates (heart medications that release nitric oxide). In a VIVUS-sponsored trial of 106 healthy men each taking avanafil and placebo, nitroglycerin given 30 minutes after avanafil caused marked hypotension (abnormally low blood pressure); no significant interaction remained at 8 hours ([Swearingen et al., 2013](https://pubmed.ncbi.nlm.nih.gov/24432037/)). Further VIVUS-sponsored interaction trials found additive drops with alpha-blockers (drugs relaxing blood vessels and the prostate) ([NCT01100021](https://clinicaltrials.gov/study/NCT01100021)), other blood-pressure drugs ([NCT01117038](https://clinicaltrials.gov/study/NCT01117038)) and alcohol ([NCT01054859](https://clinicaltrials.gov/study/NCT01054859)). Dizziness or fainting follows, with greater danger in heart disease. **Magnitude:** With nitroglycerin, symptomatic hypotension occurred in 27% of men after avanafil versus 12% after placebo; alone, a 200 mg dose lowered sitting blood pressure by 8.0/3.3 mmHg versus placebo. ### Medium πŸŸ₯ πŸŸ₯ No risk reaches Medium: the remaining risks rest on class-wide observational studies, spontaneous reports or pooled trials in which avanafil is not analyzed separately. ### Low πŸŸ₯ #### Sudden Vision Loss ⚠️ Conflicted NAION (non-arteritic anterior ischemic optic neuropathy, an optic-nerve stroke) causes vision loss. A Pfizer-funded study of days just after dosing found doubled risk ([Campbell et al., 2015](https://pubmed.ncbi.nlm.nih.gov/25358826/)); a meta-analysis pooling differently designed observational studies found none ([Penedones et al., 2020](https://pubmed.ncbi.nlm.nih.gov/31559705/)). Net reading: a small short-term risk is plausible but unproven. **Magnitude:** OR 2.15 (95% CI 1.06–4.34; OR, odds ratio, the ratio of the odds of an event) within five half-lives of use, estimated at 3 extra cases per 100,000 men aged 50+ per year with weekly use; pooled OR 1.16 (95% CI 0.89–1.52) across observational studies. #### Sudden Hearing Loss Sudden sensorineural hearing loss (rapid inner-ear hearing loss) appears in post-marketing reports for the class. In a US claims cohort of 377,722 users, risk rose slightly during use ([Liu et al., 2018](https://pubmed.ncbi.nlm.nih.gov/29512263/)). Data are observational and class-level; no avanafil-specific cases are documented. **Magnitude:** HR 1.25 (95% CI 1.01–1.55) during current use, an absolute excess of about 2 cases per 10,000 person-years (one person followed for one year). #### Priapism Priapism (a painful erection lasting over 4 hours, or over 6 hours by the label's definition) can permanently damage erectile tissue without emergency treatment. It is a class-wide warning drawn from spontaneous reports ([Wang et al., 2024](https://pubmed.ncbi.nlm.nih.gov/37724699/)); the avanafil label cites it from other drugs in the class. **Magnitude:** Not quantified in available studies. Only spontaneous reports and case reports exist, which provide no denominator for an incidence estimate for avanafil. #### Melanoma ⚠️ Conflicted Some cohorts link use of avanafil's drug class to melanoma; others do not ([Cilio et al., 2023](https://pubmed.ncbi.nlm.nih.gov/37982667/)). Sun exposure and socioeconomic status may explain the link, and avanafil users were rarely studied separately. Net reading: a causal effect is unproven, but the signal persists. **Magnitude:** Five of eight observational studies (657,984 men) report increased risk and three (360,915 men) report none; the review reports no pooled outcome figure. #### Rise in HbA1c in Type 2 Diabetes A meta-analysis found that short-acting drugs in the class, sildenafil and avanafil, did not lower HbA1c and slightly raised it in type 2 diabetes, unlike long-acting tadalafil ([Kim et al., 2025](https://pubmed.ncbi.nlm.nih.gov/39844934/)). Avanafil data were pooled with sildenafil. **Magnitude:** HbA1c rose 0.36 percentage points (95% CI 0.03–0.68) with short-acting drugs in trials of 8 weeks or longer in type 2 diabetes. #### Heart Attack, Stroke and Sudden Cardiac Death Post-marketing reports describe heart attacks, strokes and sudden cardiac deaths shortly after avanafil use, all in men with cardiovascular risk factors; the label cannot separate drug, exertion and underlying disease. Sexual activity itself briefly raises heart-attack risk ([Dahabreh & Paulus, 2011](https://pubmed.ncbi.nlm.nih.gov/21427375/)), most in habitually sedentary men. **Magnitude:** Sexual activity was linked to RR 2.70 (95% CI 1.48–4.91) for heart attack in the following hours, about 2–3 extra heart attacks per 10,000 person-years per added weekly hour of physical or sexual activity; no avanafil-specific rate exists. ### Speculative 🟨 #### Masking of Underlying Cardiovascular Disease Erectile dysfunction often precedes heart disease by several years. Treating the symptom without investigating its cause could delay detection of vascular disease; this concern rests on clinical reasoning, not controlled data. ## Risk-Modifying Factors * **Genetic polymorphisms:** No gene variant is established for avanafil risk; variants reducing CYP3A4 or CYP3A5 activity (CYP3A5 is a related drug-metabolizing liver enzyme) could raise blood levels in theory, but pharmacogenetic (gene-based drug response) data are absent. * **Baseline blood pressure:** Resting pressure below 90/50 mmHg or orthostatic hypotension (a blood-pressure drop on standing) magnifies the drop; pressure above 170/100 mmHg was excluded from trials because of cardiac risk. * **Sex:** Avanafil is approved and studied only in men; no safety data exist for women. * **Cardiovascular disease:** Recent heart attack or stroke, unstable angina (chest pain at rest or worsening), heart failure and aortic stenosis (a narrowed heart valve) raise the danger of sexual exertion and blood-pressure drops. * **Eye and ear conditions:** A "crowded" optic disc (small optic nerve head), prior NAION or retinitis pigmentosa (an inherited retinal disease) increase vulnerability to vision loss; prior sudden hearing loss warrants caution. * **Priapism-prone conditions:** Sickle cell anemia (an inherited red-blood-cell disorder), multiple myeloma (a bone-marrow cancer), leukemia and penile deformity such as Peyronie's disease (penile curvature from scar tissue) raise priapism risk. * **Kidney and liver function:** Severe kidney impairment (creatinine clearance, a kidney filtration measure, below 30 mL/min) or severe liver impairment (Child-Pugh Class C, the most advanced grade) was never studied. * **Diabetes and HbA1c:** Short-acting drugs in the class slightly raised HbA1c in type 2 diabetes trials, relevant to men with borderline glucose control. * **Age:** Men over 65 more often take alpha-blockers, blood-pressure drugs or nitrates and have orthostatic hypotension, raising fall and fainting risk; trials showed similar tolerability in older men. ## Key Interactions & Contraindications **Prescription drug interactions:** * **Nitrates (nitroglycerin, isosorbide mononitrate, isosorbide dinitrate):** Absolute contraindication; severe, potentially fatal hypotension. If a nitrate becomes medically necessary, at least 12 hours after the last avanafil dose, under close medical supervision. * **Guanylate cyclase stimulators (riociguat, vericiguat; drugs that directly raise cGMP):** Absolute contraindication; additive severe hypotension. No safe separation interval is defined. * **Strong CYP3A4 inhibitors (drugs that block CYP3A4: ketoconazole, itraconazole, ritonavir, clarithromycin, nefazodone):** Do not use per label; ketoconazole and ritonavir raised avanafil exposure about 13-fold ([NCT00770042](https://clinicaltrials.gov/study/NCT00770042)), risking hypotension and priapism. Mitigation: a different erectile dysfunction treatment. * **Moderate CYP3A4 inhibitors (erythromycin, fluconazole, diltiazem, verapamil, aprepitant):** Caution; erythromycin raised exposure about 3.6-fold, increasing hypotension and side-effect risk. Mitigation: maximum 50 mg once per 24 hours. * **CYP3A4 inducers (drugs that speed up CYP3A4: rifampin, carbamazepine, phenytoin):** Not recommended; expected to lower avanafil levels and cause treatment failure. Mitigation: alternative erectile dysfunction therapy. * **Alpha-blockers (doxazosin, terazosin, tamsulosin, alfuzosin):** Caution; additive symptomatic hypotension ([NCT01100021](https://clinicaltrials.gov/study/NCT01100021)). Mitigation: stable alpha-blocker dosing first, then avanafil starting at 50 mg. * **Blood-pressure medications (amlodipine, enalapril):** Monitor; additional 3–5 mmHg drop, and amlodipine raised avanafil exposure about 70% ([NCT01117038](https://clinicaltrials.gov/study/NCT01117038)). Mitigation: a standing blood-pressure check after the first dose. * **Other PDE5 inhibitors (sildenafil, tadalafil, vardenafil, including formulations for pulmonary hypertension, high blood pressure in the lung arteries):** Combination not recommended; additive hypotension and side effects, with no safety data. Mitigation: one PDE5 inhibitor at a time. **Over-the-counter interactions:** * **Cimetidine (an acid reducer that weakly inhibits CYP3A4):** Caution; may modestly raise avanafil levels and side effects. Mitigation: an acid reducer without CYP3A4 effects, such as famotidine. * **Unregulated "male enhancement" products:** Avoid; frequently spiked with undeclared sildenafil, tadalafil or analogs, causing additive hypotension and overdose risk. Mitigation: no co-use. **Supplement interactions:** * **St. John's wort:** Avoid; CYP3A4 induction lowers avanafil levels and efficacy. Mitigation: discontinuation of the herb before relying on avanafil. * **Goldenseal and berberine (CYP3A4-inhibiting botanicals):** Caution; may raise avanafil levels and side effects. Mitigation: the lowest dose, on days free of these products. * **Yohimbine:** Caution; raises heart rate, blood pressure and anxiety, producing unpredictable combined cardiovascular effects. Mitigation: no co-use in men with heart disease. * **Supplements with additive blood-pressure lowering (L-arginine, L-citrulline, beetroot nitrate, hawthorn, garlic extract):** Monitor; additive vasodilation can cause lightheadedness. Mitigation: separate introduction with standing blood-pressure checks. **Other interactions:** * **Alcohol:** Caution; alcohol adds blood-pressure lowering and faster heart rate ([NCT01054859](https://clinicaltrials.gov/study/NCT01054859)), dizziness becomes likelier above 3 drinks, and alcohol itself impairs erections. Mitigation: 3 standard drinks or fewer around dosing. * **Grapefruit juice:** Caution; CYP3A4 inhibition likely raises avanafil levels, increasing hypotension and side-effect risk. Mitigation: no grapefruit juice on dosing days. * **Recreational nitrates ("poppers," amyl nitrite):** Absolute contraindication; severe hypotension, collapse or heart attack. Mitigation: complete avoidance while using avanafil. * **Sauna, hot tubs and intense heat:** Caution; combined vasodilation can cause fainting. Mitigation: no prolonged heat exposure within a few hours of dosing. **Populations who should avoid Avanafil:** * Men using nitrates in any form, riociguat or vericiguat * Heart attack, stroke, life-threatening arrhythmia (heart-rhythm disorder) or coronary revascularization (stent or bypass procedure) within the past 6 months * Resting hypotension below 90/50 mmHg or uncontrolled hypertension above 170/100 mmHg * Unstable angina, angina during intercourse, or heart failure NYHA Class II or higher (New York Heart Association functional grade) * Left ventricular outflow obstruction, such as severe aortic stenosis or hypertrophic obstructive cardiomyopathy (thickened heart muscle blocking outflow) * Severe kidney impairment (creatinine clearance below 30 mL/min) or dialysis * Severe liver impairment (Child-Pugh Class C) * Hereditary degenerative retinal disorders, such as retinitis pigmentosa * Men taking strong CYP3A4 inhibitors * Known hypersensitivity to avanafil ## Risk Mitigation Strategies * **Cardiovascular screening before starting:** A cardiometabolic assessment and exercise tolerance check before first use identifies men for whom sexual exertion or blood-pressure drops pose danger, preventing cardiac events. * **Nitrate separation rule:** At least 12 hours between the last avanafil dose and any nitrate, with emergency staff informed of recent use, prevents life-threatening hypotension. * **Low starting dose in higher-risk men:** 50 mg for men on alpha-blockers or moderate CYP3A4 inhibitors, capped at 50 mg per 24 hours with inhibitors, limits hypotension and excessive drug exposure. * **Once-daily ceiling:** No more than one dose in 24 hours prevents accumulation-related headache, hypotension and priapism. * **Alcohol limit:** Keeping intake to 3 standard drinks or fewer around dosing reduces dizziness, fainting and blood-pressure drops. * **Priapism action plan:** An erection lasting beyond 4 hours prompts emergency care, preventing permanent erectile tissue damage. * **Sudden vision or hearing change protocol:** Stopping avanafil and seeking same-day evaluation for sudden vision loss or hearing loss limits progression of optic nerve or inner-ear injury. * **Annual skin examination:** A yearly full-skin check and consistent sun protection address the unresolved melanoma signal. * **Pharmacy sourcing:** Dispensing only through licensed pharmacies prevents counterfeit products with wrong doses or hidden drugs. * **Periodic cardiometabolic review:** Checking blood pressure, HbA1c and lipids every 6–12 months prevents the drug from masking progressing vascular disease. ## Therapeutic Protocol * **Standard on-demand dosing:** The labeled regimen is 100 mg about 15 minutes before sexual activity, adjusted to 200 mg or down to 50 mg (taken 30 minutes before); established in VIVUS-sponsored trials led by [Goldstein](https://pubmed.ncbi.nlm.nih.gov/22248153/) and [Hellstrom](https://pubmed.ncbi.nlm.nih.gov/25591992/). * **Dose adjustment:** In the [52-week extension](https://pubmed.ncbi.nlm.nih.gov/23521325/), 65% of men not responding to 100 mg responded to 200 mg; several attempts at each dose precede judging response. * **Daily low-dose alternative (off-label):** 50 mg daily improved erectile scores and endothelial markers in an Alexandria University trial ([Elkamshoushi et al., 2021](https://pubmed.ncbi.nlm.nih.gov/33112433/)); [Mostafa](https://pubmed.ncbi.nlm.nih.gov/27871960/) (Cairo University) reviewed low-dose continuous use of the class. * **Conventional versus integrative framing:** Conventional urology uses on-demand PDE5 inhibitors alone; integrative practitioners add exercise, weight loss, Mediterranean-style eating (vegetables, olive oil, fish) and testosterone correction, an approach popularized in Naples ([Esposito et al., 2004](https://pubmed.ncbi.nlm.nih.gov/15213209/)). Neither is the default. * **Best time of day:** Timed to anticipated sexual activity rather than the clock; the window spans about 15 minutes to 6 hours, and evening doses leave little next-day effect. * **Half-life:** Peak levels at 30–45 minutes and a half-life near 5 hours; most effect is gone by the next day, unlike tadalafil's roughly 36-hour window. * **Single versus split dosing:** Taken as a single dose, no more than once in 24 hours; splitting a dose offers no advantage. * **Food timing:** An empty stomach or light meal preserves fast onset; a high-fat meal delays peak levels by about an hour. * **Genetic polymorphisms:** No pharmacogenetic test guides dosing; interacting drugs affecting CYP3A4, not genotype, set dose limits. * **Sex-based differences:** Dosing is established only for men; no regimen exists for women. * **Age:** No dose adjustment is required for age alone; men over 65 on blood-pressure drugs or alpha-blockers commonly start at 50 mg. * **Baseline biomarkers:** Low morning testosterone or high HbA1c predict weaker response; correcting them alongside avanafil raises the chance of success. * **Pre-existing conditions:** Mild-to-moderate kidney or liver impairment needs no adjustment; men with diabetes or after prostatectomy often need 200 mg; severe impairment excludes use. ## Discontinuation & Cycling * **Short-term or long-term use:** On-demand use continues as long as erectile dysfunction persists and tolerability is good; no evidence supports lifelong continuous use for longevity. * **Withdrawal effects:** None reported; stopping returns erectile function to its untreated baseline without rebound. * **Tapering:** Not needed; no tapering protocol exists because avanafil causes no dependence or receptor adaptation. * **Cycling:** Not needed; efficacy held over 52 weeks without tolerance, so cycling offers no known benefit. * **Periodic reassessment:** Treating vascular, metabolic and hormonal causes may allow dose reduction or discontinuation when lifestyle changes restore function. ## Sourcing and Quality * **Prescription-only status:** Avanafil is a prescription medication in the US, EU and most markets; legitimate supply runs through licensed pharmacies after clinical evaluation. * **Brands and manufacturers:** Stendra (Petros Pharmaceuticals, US), Spedra (Menarini, Europe) and Zepeed (JW Pharmaceutical, South Korea); generic avanafil is sold in several countries, including India. * **Formulation:** Oral tablets in 50, 100 and 200 mg strengths; no compounded, liquid or daily-dose formulation is approved. * **Counterfeit risk:** Erectile dysfunction drugs are among the most counterfeited medicines; products from unverified websites may contain wrong doses, other PDE5 inhibitors or contaminants. * **What to look for:** Pharmacies accredited by the National Association of Boards of Pharmacy or using the ".pharmacy" domain, intact manufacturer packaging and lot numbers; third-party supplement testing does not apply to prescription drugs. * **Adulterated supplements:** "Natural" sexual-enhancement supplements are often spiked with undeclared PDE5 inhibitors or analogs, creating hidden overdose and nitrate-interaction risks when combined with avanafil. ## Practical Considerations * **Time to effect:** Effects can begin about 15 minutes after dosing and last up to roughly 6 hours; response is typically judged over several attempts at a given dose. * **Common pitfalls:** Dosing after a heavy fatty meal, expecting an erection without sexual stimulation, abandoning treatment after one failed attempt, never trying 200 mg, and combining with "poppers" (amyl nitrite). * **Regulatory status:** FDA-approved in 2012 and EU-approved in 2013 for erectile dysfunction only; daily or longevity-oriented use is off-label. * **Cost and access:** Brand avanafil costs many times more per dose than generic sildenafil or tadalafil, and insurance coverage is inconsistent. * **Payer incentives:** Insurers and national health systems favor cheaper generics and often exclude erectile dysfunction drugs, a structural incentive that may shape formularies, guidelines and research funding. * **Evidence funding:** Most avanafil trials were sponsored by VIVUS or regional licensees, while the largest recent comparative analysis involved employees of a competitor; both are financial conflicts of interest. * **Fertility:** Daily 100 mg for 26 weeks did not affect sperm count, motility or morphology in a [placebo-controlled trial](https://clinicaltrials.gov/study/NCT01768676), relevant for men planning conception. ## Interaction with Foundational Habits * **Sleep:** Indirect. Avanafil has no known direct effect on sleep, and its short half-life avoids overnight carryover, though nasal congestion after evening doses can briefly disturb breathing. Poor sleep and untreated sleep apnea (breathing pauses during sleep) lower testosterone and erectile function, limiting drug response. * **Nutrition:** Direct. A high-fat meal delays peak levels by about an hour and blunts them; grapefruit juice raises levels through CYP3A4 inhibition. Mediterranean-style eating improves erectile and vascular function, and dietary nitrates (beets, leafy greens) may add mild blood-pressure lowering. * **Exercise:** Potentiating. Aerobic and resistance training improve endothelial function and erectile response, complementing avanafil. Hard exertion shortly after dosing, especially in heat, can add to vasodilation and lightheadedness; no evidence shows the drug blunts training adaptations. * **Stress management:** Indirect. Stress and performance anxiety raise sympathetic tone (the fight-or-flight nervous system), constricting penile vessels and counteracting avanafil. Reliable drug response can ease anticipatory anxiety, while mindfulness, sex therapy or couples counseling address psychological causes the drug does not treat. ## Monitoring Protocol & Defining Success Baseline testing before starting establishes whether sexual activity is safe and identifies treatable causes of erectile dysfunction: resting and standing blood pressure, HbA1c, an apolipoprotein-based lipid assessment, morning testosterone, kidney and liver function, and a validated erectile-function questionnaire score. Symptoms of chest pain, breathlessness on exertion, prior vision or hearing loss, and all current medications and supplements are reviewed at the same visit to catch nitrate use and CYP3A4 interactions. Ongoing monitoring follows a set cadence: erectile response and side effects are reassessed after about 4 weeks or 4–8 doses, blood pressure is rechecked after each dose change, and the laboratory panel and questionnaire are repeated every 6–12 months. New visual or hearing symptoms prompt immediate evaluation rather than waiting for scheduled testing. | Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes | |-----------|--------------------------|-----------------|---------------| | Blood pressure (seated and standing) | 110–120/70–80 mmHg; never below 90/50 | Hypotension risk; vascular health | Conventional target below 130/80; standing reading after 1–3 minutes detects orthostatic hypotension | | HbA1c | 4.8–5.4% | Predicts response; class glucose effect | Conventional normal below 5.7%; no fasting needed | | ApoB | Below 80 mg/dL (below 60 mg/dL if high risk) | Atherosclerosis driving vascular dysfunction | ApoB (apolipoprotein B, the protein on each artery-clogging lipoprotein particle); conventional labs report LDL (low-density lipoprotein) cholesterol below 100 mg/dL instead; fasting optional | | Morning total testosterone | 500–900 ng/dL | Low levels blunt response | Drawn 7–10 a.m.; conventional range about 264–916 ng/dL; paired with free testosterone and SHBG (sex hormone-binding globulin, its carrier protein) | | eGFR | Above 90 mL/min/1.73 mΒ² | Severe kidney impairment excludes use | eGFR (estimated glomerular filtration rate, kidney filtering capacity); conventional normal above 60; avanafil not used below 30 creatinine clearance | | ALT | Below 25 U/L | Severe liver impairment excludes use | ALT (alanine aminotransferase, a liver-cell enzyme); conventional upper limit about 40–45 U/L; paired with AST (aspartate aminotransferase, a second liver enzyme) | | IIEF-5 questionnaire score | 22–25 | Tracks treatment response | IIEF-5 (five-item erectile-function questionnaire, also called SHIM, Sexual Health Inventory for Men); conventional cutoff 22 or higher means no dysfunction; compared with personal baseline | **Qualitative markers:** * Erection firmness and reliability across attempts * Time from dosing to adequate erection * Sexual confidence, satisfaction and partner satisfaction * Headache, flushing or nasal congestion frequency and severity * Any dizziness on standing after dosing * Any change in vision, color perception or hearing ## Emerging Research * **Tadalafil for Alzheimer's disease:** An Imperial College London phase 2 trial ([NCT07172815](https://clinicaltrials.gov/study/NCT07172815)), not yet recruiting, will randomize 244 people with mild cognitive impairment or early Alzheimer's to a year of tadalafil or placebo, primarily testing safety. Positive results would strengthen class-level brain claims; avanafil's short action may not replicate them. * **Brain small-vessel disease:** The ETLAS-2 phase 2 trial ([NCT05173896](https://clinicaltrials.gov/study/NCT05173896)) of daily tadalafil in 76 patients with small-vessel brain disease missed its adherence target and showed no cognitive or blood-pressure benefit, only a nonsignificant trend toward less white-matter damage ([Γ–lmestig et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40718899/)), weakening class brain claims pending larger, lower-dose trials. * **Daily avanafil and vessel health:** A completed Alexandria University phase 4 trial of daily avanafil ([NCT04374994](https://clinicaltrials.gov/study/NCT04374994), 70 participants) and a related randomized study ([Elkamshoushi et al., 2021](https://pubmed.ncbi.nlm.nih.gov/33112433/)) reported improved endothelial markers; trials with vascular outcomes would test clinical relevance. * **Spinal cord injury:** A phase 4 trial comparing avanafil with sildenafil in 78 men with spinal cord injury ([NCT03169582](https://clinicaltrials.gov/study/NCT03169582)) has unknown status and no posted results. * **Head-to-head comparisons:** A Zydus-sponsored trial found avanafil superior to sildenafil ([Kumar et al., 2022](https://pubmed.ncbi.nlm.nih.gov/35080051/)), whereas a Viatris-co-authored network meta-analysis ranked it lowest ([Salonia et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42296271/)). Independent comparisons could move avanafil's standing either way. * **Metabolic signal:** The finding that short-acting drugs in the class raised HbA1c in type 2 diabetes ([Kim et al., 2025](https://pubmed.ncbi.nlm.nih.gov/39844934/)) could weaken avanafil's case for men with diabetes if confirmed in avanafil-specific trials. * **Cardiovascular and mortality signal:** Cohort benefits ([Soulaidopoulos et al., 2024](https://pubmed.ncbi.nlm.nih.gov/38777751/)) await randomized confirmation; any benefit may depend on continuous exposure, favoring long-acting drugs over on-demand avanafil. * **Large drug-safety studies:** Larger studies of optic neuropathy ([Campbell et al., 2015](https://pubmed.ncbi.nlm.nih.gov/25358826/)) and melanoma ([Cilio et al., 2023](https://pubmed.ncbi.nlm.nih.gov/37982667/)) could confirm or dismiss class-wide signals, shifting the risk side of the balance. * **New formulations:** Oil-based formulations that disperse into tiny droplets in the gut, and other delivery systems, aim for faster onset and higher bioavailability (the fraction of a dose reaching the blood) ([Fahmy et al., 2015](https://pubmed.ncbi.nlm.nih.gov/25168449/)); these remain at an early stage, tested mostly in laboratory and animal studies. ## Conclusion Avanafil is a fast-acting prescription medication for erectile dysfunction and the newest of the widely approved drugs in its family. For health-focused men, its clearest strength is reliable, well-documented improvement in erections, including in men with diabetes or after prostate surgery, with effects that start quickly and fade within hours. That short action suits men who value spontaneity and dislike lingering side effects. Its common side effects are familiar and usually mild: headache, flushing and nasal congestion. The serious hazards are uncommon but real, above all dangerous blood-pressure drops when combined with heart medications called nitrates, plus rare reports of sudden vision or hearing loss and prolonged erections. Signals linking the drug family to skin cancer remain unsettled. The evidence for the erectile benefit is strong, yet most of it comes from studies paid for by the companies selling avanafil, and one large comparison ranking it below rival drugs was co-written by staff of a rival's maker. Hopes that this drug family protects the heart and brain rest on studies that followed users over time rather than controlled experiments, controlled trials show only small gains in blood-vessel function, and nearly all this research involves longer-acting relatives, so whether occasional doses of a short-acting drug carry any of these effects is unknown. Overall, avanafil is a well-supported option for improving sexual function, with a quick, short-lived profile, while its role in longer-term health remains uncertain. **[Top](#top) - [Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol)**